What is the appropriate treatment for a patient with hyperosmolar hyperglycemic state and concurrent metabolic encephalopathy due to metabolic‑associated steatohepatitis (MASLD)?

Treatment for HHS with Concurrent Metabolic Encephalopathy due to MASLD

Treat both conditions simultaneously: aggressively manage the HHS with fluid resuscitation, insulin therapy, and electrolyte correction while initiating lactulose for the hepatic encephalopathy, recognizing that HHS itself is likely the precipitating factor for the encephalopathy.

Immediate Management Priorities

1. Address the HHS First (Primary Precipitant)

The hyperosmolar hyperglycemic state is almost certainly the precipitating factor for the metabolic encephalopathy 1, 2. Controlling precipitating factors is paramount, as nearly 90% of hepatic encephalopathy patients can be treated with just correction of the precipitating factor 1.

HHS Management Protocol 3, 4:

• Fluid resuscitation: Aggressive IV fluid replacement to restore circulatory volume and tissue perfusion
• Insulin therapy: Continuous IV insulin is standard of care for critically ill patients with altered mental status
• Electrolyte monitoring and correction: Particularly potassium and phosphate
• Gradual osmolality reduction: Maximum reduction of 3 mOsm/kg H₂O per hour to prevent cerebral edema 3
• Target glucose: Maintain 250-300 mg/dL until hyperosmolarity and mental status improve 3

2. Concurrent Hepatic Encephalopathy Treatment

Four-Pronged Approach 1:

1. Airway protection: Patients with higher grades of HE who cannot protect their airway need ICU-level monitoring 1

2. Rule out alternative causes: While HHS is the likely precipitant, exclude other causes of altered mental status in this critically ill patient 1

3. Identify and treat precipitating factors: The HHS is your primary target here 1, 2

4. Empirical HE treatment with lactulose 1:

   • Initial dosing: 25 mL lactulose syrup every 12 hours (or via nasogastric tube if unable to swallow safely)
   • Target: 2-3 soft bowel movements per day
   • For severe HE (Grade ≥3): Consider lactulose enema (300 mL lactulose + 700 mL water, 3-4 times daily, retained for 30 minutes) 2

Critical Management Considerations

Avoid Lactulose Overuse

Do not give excessive lactulose doses 1. Overuse can cause aspiration (particularly dangerous in an obtunded patient), dehydration (compounding the HHS), hypernatremia (worsening hyperosmolarity), and can paradoxically precipitate HE 1.

Monitor for Cerebral Edema

This patient faces dual risks for cerebral edema:

• From HHS treatment: Rapid osmolality decline when treating HHS 3
• From hepatic encephalopathy: Though rare in adults with chronic liver disease

Warning signs 3: Deteriorating consciousness, seizures, bradycardia, pupillary changes. If these develop, mortality is 70%.

Fluid Management Balance

You must balance:

• Aggressive fluid resuscitation needed for HHS 3, 4
• Risk of overhydration in a patient with chronic liver disease
• Lactulose-induced diarrhea causing additional fluid losses

Consider albumin infusion 1, 2: Recent evidence shows IV albumin (1.5 g/kg/day) in combination with lactulose improved recovery rates (75% vs 53.3%, P=0.03) and post-discharge survival in overt HE patients 2. This may be particularly beneficial given the dual need for volume expansion in HHS and potential benefit in HE.

Additional Therapeutic Options

If Lactulose Alone is Insufficient

• Rifaximin: Can be added to lactulose, though solid data do not support rifaximin alone 1. This is more relevant for secondary prophylaxis after recovery 1, 5
• IV L-ornithine L-aspartate (LOLA): May improve persistent HE 1
• Oral BCAAs: Can be used as alternative or additional therapy 1, 2

Regarding the MASLD Component

Do not initiate MASLD-specific therapy during this acute crisis 6. The MASLD is a chronic condition; focus on the acute life-threatening HHS and its complication (HE). After stabilization, the patient should receive standard AIH treatment if indicated, with attention to metabolic syndrome management 6.

Transition Planning

Once the patient stabilizes:

• Transition from IV to subcutaneous insulin: Administer basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia 4
• Secondary prophylaxis for HE: Continue lactulose titrated to 2-3 bowel movements daily 1, 5
• Address underlying MASLD: Consider GLP-1 receptor agonists or SGLT2 inhibitors for long-term management, as these improve both diabetes control and hepatic steatosis 7, 8, 9

Key Pitfall to Avoid

The most common error would be treating these as separate conditions sequentially rather than recognizing that the HHS is driving the encephalopathy 1, 2, 1. Treat both simultaneously, but understand that resolving the hyperosmolar state will likely resolve or significantly improve the encephalopathy.